Lumos Pharma (FRA:4NX1) Dividend Payout Ratio : 0.00 (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma Dividend Payout Ratio?

Lumos Pharma's dividend payout ratio for the months ended in Mar. 2024 was 0.00.

The historical rank and industry rank for Lumos Pharma's Dividend Payout Ratio or its related term are showing as below:

FRA:4NX1's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.435
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-21), the Dividend Yield % of Lumos Pharma is 0.00%.

Lumos Pharma's Dividends per Share for the months ended in Mar. 2024 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Lumos Pharma Dividend Payout Ratio Historical Data

The historical data trend for Lumos Pharma's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Pharma Dividend Payout Ratio Chart

Lumos Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

Lumos Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Lumos Pharma's Dividend Payout Ratio

For the Biotechnology subindustry, Lumos Pharma's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumos Pharma's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumos Pharma's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Lumos Pharma's Dividend Payout Ratio falls into.

Lumos Pharma Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Lumos Pharma's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	0
	=	N/A

Lumos Pharma's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	0
	=	N/A

Lumos Pharma (FRA:4NX1) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Lumos Pharma Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Lumos Pharma's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Pharma (FRA:4NX1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (FRA:4NX1) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

LUMO:USA

Address

4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756

Website

https://www.lumos-pharma.com

Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.

Lumos Pharma (FRA:4NX1) Headlines

No Headlines